Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Seer is focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease.
Seer was founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer. The company is headquartered in South San Francisco, California.
Seer's novel Proteograph™ platform allows for the first-ever generation of proteomic information with high accuracy at a scale and speed not previously possible, complementing genomic and other health information, with a goal of enabling breakthroughs in the most challenging research and clinical problems, such as early disease detection.
Seer is advancing a portfolio of first-in-class liquid biopsy products to detect disease at early, pre-symptomatic stages to drive earlier treatment and improved outcomes.
Seer is backed by Maverick Ventures, aMoon Fund, T. Rowe Price, Aju IB Investment, Wing Venture Capital and others. The company raised $55M in a Series D financing on Dec 17, 2019. This new round brings Seer's total funding to $108.5M to date.